Loading
Economic and Financial Impacts of Cancer / Lung Cancer Diagnosis and Treatment · Journal article
Expert Review of Pharmacoeconomics & Outcomes Research · August 18, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a single-center retrospective budget-impact model projecting that weight-banded pembrolizumab dosing could reduce institutional drug consumption by 25% and generate annual savings of €1.1–11.2 million (institutional to national extrapolation). The analysis assumes clinical equivalence and regulatory feasibility but provides no safety, efficacy, or prospective clinical data to support implementation.
Retrospective, single-center pharmacoeconomic model. Adults with advanced non-oncogene-addicted non-small cell lung cancer treated at Clinical Hospital Centre Rijeka, Croatia, during 2024.. Intervention: Simulated weight-banded pembrolizumab dosing stratified by body weight (<65 kg, 65–90 kg, ≥90 kg).. Compared with: Standard flat-dose pembrolizumab (200 mg every three weeks or 400 mg every six weeks).. n = 96. Single center: Clinical Hospital Centre Rijeka, Croatia..
Weight-banded dosing reduced institutional drug consumption by 25% Institutional annual savings exceeded €1.1 million National extrapolation projected savings of €3.7–11.2 million annually (assuming Rijeka accounts for 10–30% of national use)
No clinical efficacy, safety, or pharmacodynamic data provided; equivalence of weight-banded and flat dosing is assumed, not demonstrated.
Clinicians and health-system decision-makers should recognize this as a cost-modeling exercise without clinical validation. The authors explicitly call for prospective clinical validation and assessment of pharmacodynamic, safety, and regulatory implications before implementation; until such data exist, this projection should not inform dosing practice.
A single-center retrospective pharmacoeconomic model with simulated dosing strategy and no clinical outcome data; findings require prospective validation before implementation.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians and health-system decision-makers should recognize this as a cost-modeling exercise without clinical validation. The authors explicitly call for prospective clinical validation and assessment of pharmacodynamic, safety, and regulatory implications before implementation; until such data exist, this projection should not inform dosing practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
BACKGROUND: Pembrolizumab is among the costliest anticancer therapies; fixed dosing may cause drug wastage, particularly in lower-weight patients, adding to health-system budgetary pressure. RESEARCH DESIGN AND METHODS: This retrospective, single-center pharmacoeconomic analysis compared standard flat-dose pembrolizumab (200 mg every three weeks [Q3W] or 400 mg every six weeks [Q6W]) with a simulated weight-banded strategy (<65 kg, 65-90 kg, ≥90 kg) in adults with advanced non-oncogene-addicted non-small cell lung cancer treated at the Clinical Hospital Centre Rijeka, Croatia, during 2024. Institutional and national public-payer budget impact was modeled using list drug-acquisition prices, with one-way and probabilistic sensitivity analyses. RESULTS: Ninety-six patients received pembrolizumab during the study period. Weight-banded dosing reduced institutional drug consumption by 25%, yielding annual savings exceeding €1.1 million. National extrapolation, assuming Rijeka accounts for 10-30% of national pembrolizumab use, projected savings of €3.7-11.2 million annually. CONCLUSIONS: Weight-banded pembrolizumab dosing may reduce drug expenditure without evidence of compromised outcomes in this economic model; prospective clinical validation and consideration of pharmacodynamic, safety, and regulatory implications are warranted before implementation.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.